{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:16:56Z","timestamp":1791389816473,"version":"4.3.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Health Promotion for Wellness and Development Project - Special Programme for Oncology Research by the Oasis for Life Public Welfare Service Centre","award":["BJHA-CRP-062"],"award-info":[{"award-number":["BJHA-CRP-062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74496-0","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T07:02:24Z","timestamp":1727852544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Jietao","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"issue":"1","key":"74496_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020Data","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki, M. et al. Metastatic sites and survival in lung cancer. Lung Cancer.86(1), 78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020Data (2014).","journal-title":"Lung Cancer."},{"issue":"suppl_16","key":"74496_CR2","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1200\/JCO.2022.40.16_suppl.9096","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS). J. Clin. Oncol.40(suppl_16), 9096\u20139096 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"74496_CR3","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jtho.2022.07.1143","volume":"17","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Central nervous system efficacy of Furmonertinib (AST2818) versus Gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the FURLONG study. J. Thorac. Oncol.17(11), 1297\u20131305. https:\/\/doi.org\/10.1016\/j.jtho.2022.07.1143 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"74496_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana, T. et al. CNS response to Osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J. Clin. Oncol.https:\/\/doi.org\/10.1200\/JCO.2018.78.3118 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"74496_CR5","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.3390\/cancers16142589","volume":"16","author":"I Attili","year":"2024","unstructured":"Attili, I. et al. Post-progression analysis of EGFR-mutant NSCLC following osimertinib therapy in real-world settings. Cancers (Basel).16(14), 2589. https:\/\/doi.org\/10.3390\/cancers16142589 (2024).","journal-title":"Cancers (Basel)."},{"issue":"31","key":"74496_CR6","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1200\/JCO.21.02911","volume":"40","author":"E Miyauchi","year":"2022","unstructured":"Miyauchi, E. et al. Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR. J. Clin. Oncol.40(31), 3587\u20133592. https:\/\/doi.org\/10.1200\/JCO.21.02911 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"74496_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","volume":"39","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q. et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell.39(9), 1279-1291.e3. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.005 (2021).","journal-title":"Cancer Cell."},{"issue":"suppl_2","key":"74496_CR8","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/S0923-7534(23)04149-2","volume":"34","author":"BC Cho","year":"2023","unstructured":"Cho, B. C. et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial. Ann. Oncol.34(suppl_2), S1254\u2013S1335. https:\/\/doi.org\/10.1016\/S0923-7534(23)04149-2 (2023).","journal-title":"Ann. Oncol."},{"issue":"7","key":"74496_CR9","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.6(7), e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097 (2009).","journal-title":"PLoS Med."},{"issue":"10","key":"74496_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston, M. et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst. Rev.10(10), 142. https:\/\/doi.org\/10.1002\/14651858.ED000142 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7414","key":"74496_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ.327(7414), 557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557 (2003).","journal-title":"BMJ."},{"key":"74496_CR12","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2023. Available from: https:\/\/www.R-project.org\/."},{"key":"74496_CR13","unstructured":"Bender, R., Grouven, U., Bender, F. netmeta: Network Meta-Analysis Using Frequentist Methods. R package version 2.9.0. Vienna, Austria: R Foundation for Statistical Computing; 2022. Available from: https:\/\/cran.r-project.org\/package=netmeta."},{"key":"74496_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/9780470712184.ch8","volume-title":"Cochrane handbook for systematic reviews of interventions: cochrane book series","author":"JP Higgins","year":"2008","unstructured":"Higgins, J. P. & Altman, D. G. Assessing risk of bias in included studies. In Cochrane handbook for systematic reviews of interventions: cochrane book series (eds Higgins, J. P. & Green, S.) 187\u2013241 (John Wiley & Sons, Chichester, 2008). https:\/\/doi.org\/10.1002\/9780470712184.ch8."},{"issue":"5","key":"74496_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito, H. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol.20(5), 625\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(19)30035-X (2019).","journal-title":"Lancet Oncol."},{"issue":"1","key":"74496_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","volume":"10","author":"Y Kawashima","year":"2022","unstructured":"Kawashima, Y. et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir. Med.10(1), 72\u201382. https:\/\/doi.org\/10.1016\/S2213-2600(21)00166-1 (2022).","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"74496_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cncr.34553","volume":"129","author":"Y Lee","year":"2023","unstructured":"Lee, Y. et al. A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation. Cancer.129(3), 405\u2013414. https:\/\/doi.org\/10.1002\/cncr.34553 (2023).","journal-title":"Cancer."},{"issue":"9","key":"74496_CR18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006(WJOG9717L)","volume":"17","author":"H Kenmotsu","year":"2022","unstructured":"Kenmotsu, H. et al. Randomized Phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study. J Thorac Oncol.17(9), 1098\u20131108. https:\/\/doi.org\/10.1016\/j.jtho.2022.05.006(WJOG9717L) (2022).","journal-title":"J Thorac Oncol."},{"issue":"Suppl_2","key":"74496_CR19","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/j.annonc.2023.10.071","volume":"34","author":"Y Nakahara","year":"2023","unstructured":"Nakahara, Y. et al. LBA70 (OSIRAM-1) OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833). Ann. Oncol.34(Suppl_2), S1254\u2013S1335. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.071 (2023).","journal-title":"Ann. Oncol."},{"issue":"Suppl_2","key":"74496_CR20","doi-asserted-by":"publisher","first-page":"S1313","DOI":"10.1016\/j.annonc.2023.10.072","volume":"34","author":"X Le","year":"2023","unstructured":"Le, X. et al. LBA71 RAMOSE: A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKi-naive EGFR, mutant metastatic NSCLC (RAMOSE trial). Ann. Oncol.34(Suppl_2), S1313\u2013S1314. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.072 (2023).","journal-title":"Ann. Oncol."},{"issue":"9","key":"74496_CR21","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","volume":"16","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Apatinib Plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706). J. Thorac. Oncol.16(9), 1533\u20131546. https:\/\/doi.org\/10.1016\/j.jtho.2021.05.006 (2021).","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"74496_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park, K. et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol.17(5), 577\u2013589. https:\/\/doi.org\/10.1016\/S1470-2045(16)30033-X (2016).","journal-title":"Lancet Oncol."},{"issue":"2","key":"74496_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares, L. et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann. Oncol.28(2), 270\u2013277. https:\/\/doi.org\/10.1093\/annonc\/mdw611 (2017).","journal-title":"Ann. Oncol."},{"issue":"27","key":"74496_CR24","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J. Clin. Oncol.40(27), 3162\u20133171. https:\/\/doi.org\/10.1200\/JCO.21.02641 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"74496_CR25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","volume":"10","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir. Med.10(11), 1019\u20131028. https:\/\/doi.org\/10.1016\/S2213-2600(22)00168-0 (2022).","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"74496_CR26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir. Med.11(10), 905\u2013915. https:\/\/doi.org\/10.1016\/S2213-2600(23)00183-2 (2023).","journal-title":"Lancet Respir. Med."},{"issue":"26","key":"74496_CR27","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.23.00515","volume":"41","author":"BC Cho","year":"2023","unstructured":"Cho, B. C. et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301. J. Clin. Oncol.41(26), 4208\u20134217. https:\/\/doi.org\/10.1200\/JCO.23.00515 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"74496_CR28","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2023.06.016","volume":"18","author":"T Reungwetwattana","year":"2023","unstructured":"Reungwetwattana, T. et al. Lazertinib Versus gefitinib tyrosine kinase inhibitors in treatment-na\u00edve patients with EGFR-mutated advanced NSCLC: analysis of the Asian subpopulation in LASER301. J. Thorac. Oncol.18(10), 1351\u20131361. https:\/\/doi.org\/10.1016\/j.jtho.2023.06.016 (2023).","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"74496_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4143\/crt.2023.453","volume":"56","author":"KH Lee","year":"2024","unstructured":"Lee, K. H. et al. Lazertinib versus gefitinib as first-line treatment for EGFR-mutated locally advanced or metastatic NSCLC: LASER301 Korean subset. Cancer Res. Treat.56(1), 48\u201360. https:\/\/doi.org\/10.4143\/crt.2023.453 (2024).","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"74496_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med.378(2), 113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"74496_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol.16(2), 165\u2013176. https:\/\/doi.org\/10.1007\/s11523-021-00794-6 (2021).","journal-title":"Target Oncol."},{"issue":"1","key":"74496_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med.382(1), 41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"74496_CR33","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.jtho.2023.08.017","volume":"18","author":"RA Soo","year":"2023","unstructured":"Soo, R. A. et al. Central nervous system outcomes of lazertinib versus gefitinib in EGFR-mutated advanced NSCLC: a LASER301 subset analysis. J. Thorac. Oncol.18(12), 1756\u20131766. https:\/\/doi.org\/10.1016\/j.jtho.2023.08.017 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"74496_CR34","unstructured":"Wu, Y. L., Zhou, Q., Wang, J., et al. Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non\u2013small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. American Society of Clinical Oncology Annual Meeting; June 2023; Chicago: Abstract 9001."},{"issue":"2","key":"74496_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi, Y. et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J. Clin. Oncol.38(2), 115\u2013123. https:\/\/doi.org\/10.1200\/JCO.19.01488 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"74496_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","volume":"38","author":"V Noronha","year":"2020","unstructured":"Noronha, V. et al. Gefitinib Versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J. Clin. Oncol.38(2), 124\u2013136. https:\/\/doi.org\/10.1200\/JCO.19.01154 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"74496_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55050","volume":"6","author":"X Hou","year":"2023","unstructured":"Hou, X. et al. Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non-small cell lung cancer in patients with brain metastases: the GAP BRAIN open-label, randomized, multicenter, phase 3 study. JAMA Netw. Open.6(2), e2255050. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55050 (2023).","journal-title":"JAMA Netw. Open."},{"issue":"21","key":"74496_CR38","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med.389(21), 1935\u20131948. https:\/\/doi.org\/10.1056\/NEJMoa2306434 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"suppl_3","key":"74496_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/esmoop\/esmoop102569","volume":"9","author":"NI Valdiviezo Lama","year":"2024","unstructured":"Valdiviezo Lama, N. I. et al. First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes. Ann. Oncol.9(suppl_3), 1\u201353. https:\/\/doi.org\/10.1016\/esmoop\/esmoop102569 (2024).","journal-title":"Ann. Oncol."},{"key":"74496_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107349","volume":"184","author":"T Ninomiya","year":"2023","unstructured":"Ninomiya, T. et al. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-na\u00efve patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer.184, 107349. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107349 (2023).","journal-title":"Lung Cancer."},{"issue":"8","key":"74496_CR41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2024.2362889","volume":"24","author":"T Landre","year":"2024","unstructured":"Landre, T. et al. First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials. Expert Rev. Anticancer Ther.24(8), 775\u2013780. https:\/\/doi.org\/10.1080\/14737140.2024.2362889 (2024).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"20","key":"74496_CR42","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard, P. et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin. Cancer Res.22(20), 5130\u20135140. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0399 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"74496_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough, N. et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin. Cancer Res.27(1), 189\u2013201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1871 (2021).","journal-title":"Clin. Cancer Res."},{"key":"74496_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","volume":"170","author":"M Johnson","year":"2022","unstructured":"Johnson, M., Garassino, M. C., Mok, T. & Mitsudomi, T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies. Lung Cancer.170, 41\u201351. https:\/\/doi.org\/10.1016\/j.lungcan.2022.05.011 (2022).","journal-title":"Lung Cancer."},{"key":"74496_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863666","volume":"12","author":"XF Yi","year":"2022","unstructured":"Yi, X. F. et al. Efficacy of osimertinib in EGFR-mutated advanced non-small-cell lung cancer with different T790M status following resistance to prior EGFR-TKIs: a systematic review and meta-analysis. Front Oncol.12, 863666. https:\/\/doi.org\/10.3389\/fonc.2022.863666 (2022).","journal-title":"Front Oncol."},{"key":"74496_CR46","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1016\/j.jtho.2023.09.596","volume":"18","author":"CB Han","year":"2023","unstructured":"Han, C. B. et al. Efficacy of aumolertinib in EGFR T790M-negative or -unknown NSCLC with brain metastases following resistance to prior EGFR-TKIs. J. Thorac. Oncol.18, S341. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.596 (2023).","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"74496_CR47","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-019-1240-x","volume":"38","author":"S La Monica","year":"2019","unstructured":"La Monica, S. et al. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J. Exp. Clin. Cancer Res.38(1), 222. https:\/\/doi.org\/10.1186\/s13046-019-1240-x (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"74496_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102820","volume":"146","author":"SE Rebuzzi","year":"2020","unstructured":"Rebuzzi, S. E. et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives. Crit. Rev. Oncol. Hematol.146, 102820. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102820 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"74496_CR49","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00073","volume":"7","author":"M Mosca","year":"2023","unstructured":"Mosca, M. et al. First-generation epidermal growth factor receptor inhibitors plus antiangiogenic drugs versus third-generation epidermal growth factor receptor inhibitors in advanced non-small-cell lung cancer: a meta-analysis. JCO Precis. Oncol.7, e2300073. https:\/\/doi.org\/10.1200\/PO.23.00073 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"74496_CR50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2019.08.021","volume":"121","author":"T Jiang","year":"2019","unstructured":"Jiang, T. et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases. Eur. J. Cancer.121, 98\u2013108. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.021 (2019).","journal-title":"Eur. J. Cancer."},{"issue":"10","key":"74496_CR51","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-08-2407","volume":"15","author":"N Schicher","year":"2009","unstructured":"Schicher, N. et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin. Cancer Res.15(10), 3495\u20133502. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2407 (2009).","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"74496_CR52","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","volume":"15","author":"GN Naumov","year":"2009","unstructured":"Naumov, G. N. et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res.15(10), 3484\u20133494. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2904 (2009).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"74496_CR53","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"H Akamatsu","year":"2021","unstructured":"Akamatsu, H. et al. Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan Oncology Group 8715L Phase 2 randomized clinical trial. JAMA Oncol.7(3), 386\u2013394. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6758 (2021).","journal-title":"JAMA Oncol."},{"key":"74496_CR54","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.annonc.2021.04.010","volume":"32","author":"R Soo","year":"2021","unstructured":"Soo, R. et al. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): results from the ETOP BOOSTER trial. Ann. Oncol.32, 942\u2013944. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.010 (2021).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74496-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T07:08:00Z","timestamp":1727852880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74496-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74496"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74496-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22901"}}